Clinical Trial Update: The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing RCD versus BCD regimens in newly diagnosed Waldenström macroglobulinemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Waldenström Macroglobulinemia | Phase 4 | Status: COMPLETED